KMT2A and leukemia: We used CD14 as a marker of myeloid differentiation and CD33 as a marker for immature and aggressive leukemia [31] to characterize our CRISPR/Cas9 MLL-AF4 and MLL-AF9 cells before and following treatment with CAD204520.